

# Chiaki Nakaseko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7743459/publications.pdf>

Version: 2024-02-01

130  
papers

1,556  
citations

304743

22  
h-index

361022

35  
g-index

131  
all docs

131  
docs citations

131  
times ranked

2491  
citing authors

#	ARTICLE	IF	CITATIONS
1	Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. <i>Blood</i> , 2003, 102, 4236-4242.	1.4	120
2	Markedly upregulated serum interleukin-12 as a novel biomarker in POEMS syndrome. <i>Neurology</i> , 2012, 79, 575-582.	1.1	81
3	Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. <i>International Journal of Hematology</i> , 2011, 93, 602-609.	1.6	65
4	Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans. <i>Nature Communications</i> , 2015, 6, 8951.	12.8	59
5	Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 4817-4830.	7.0	59
6	Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 375-382.	1.6	57
7	Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1346-1348.	1.9	57
8	Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. <i>Cancer Science</i> , 2018, 109, 182-192.	3.9	54
9	Restrictive usage of monoclonal immunoglobulin $\lambda$ light chain germline in POEMS syndrome. <i>Blood</i> , 2008, 112, 836-839.	1.4	52
10	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. <i>Blood</i> , 2015, 126, 415-422.	1.4	49
11	Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. <i>Haematologica</i> , 2014, 99, 1817-1825.	3.5	44
12	Reactivation of Hepatitis B Virus in Hematopoietic Stem Cell Transplant Recipients in Japan: Efficacy of Nucleos(t)ide Analogues for Prevention and Treatment. <i>International Journal of Molecular Sciences</i> , 2014, 15, 21455-21467.	4.1	38
13	Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. <i>Blood</i> , 2018, 131, 2173-2176.	1.4	36
14	Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplantation Outcomes? A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1553-1559.	2.0	35
15	Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial). <i>Blood</i> , 2016, 128, 791-791.	1.4	31
16	Multiple angiogenetic factors are upregulated in POEMS syndrome. <i>Annals of Hematology</i> , 2013, 92, 245-248.	1.8	30
17	Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. <i>International Journal of Hematology</i> , 2019, 109, 426-439.	1.6	29
18	Genetic and transcriptional landscape of plasma cells in POEMS syndrome. <i>Leukemia</i> , 2019, 33, 1723-1735.	7.2	28

#	ARTICLE	IF	CITATIONS
19	The Soluble Form of LR11 Protein Is a Regulator of Hypoxia-induced, Urokinase-type Plasminogen Activator Receptor (uPAR)-mediated Adhesion of Immature Hematological Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 11877-11886.	3.4	27
20	Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes. <i>Experimental and Molecular Medicine</i> , 2014, 46, e89-e89.	7.7	25
21	Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy. <i>Clinical Neurophysiology</i> , 2014, 125, 381-387.	1.5	25
22	A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 101, 154-164.	1.6	23
23	Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. <i>Clinica Chimica Acta</i> , 2012, 413, 1542-1548.	1.1	22
24	KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis. <i>Blood Advances</i> , 2019, 3, 2537-2549.	5.2	22
25	Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. <i>International Journal of Hematology</i> , 2018, 107, 327-336.	1.6	20
26	Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. <i>International Journal of Hematology</i> , 2011, 93, 624-632.	1.6	19
27	Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1180-1186.	2.0	19
28	Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. <i>Annals of Hematology</i> , 2018, 97, 655-662.	1.8	18
29	Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients). <i>Blood</i> , 2012, 120, 167-167.	1.4	17
30	Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) vs Next-Generation Sequencing. <i>Blood</i> , 2020, 136, 22-23.	1.4	17
31	Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. <i>International Journal of Hematology</i> , 2012, 95, 409-419.	1.6	16
32	Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation. <i>Leukemia Research Reports</i> , 2013, 2, 67-69.	0.4	16
33	Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. <i>Leukemia Research</i> , 2016, 50, 85-94.	0.8	15
34	Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>PLoS ONE</i> , 2019, 14, e0221941.	2.5	15
35	Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. <i>American Journal of Hematology</i> , 2004, 76, 368-372.	4.1	14
36	Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1. <i>Oncotarget</i> , 2015, 6, 5102-5117.	1.8	14

#	ARTICLE	IF	CITATIONS
37	LR11: a novel biomarker identified in follicular lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 277-280.	2.5	13
38	Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma. <i>Clinica Chimica Acta</i> , 2014, 430, 48-54.	1.1	13
39	Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy. <i>International Journal of Hematology</i> , 2012, 95, 204-208.	1.6	11
40	Autologous Stem Cell Transplantation for POEMS Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 21-23.	0.4	11
41	Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. <i>International Journal of Hematology</i> , 2020, 111, 65-74.	1.6	11
42	Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212. <i>Blood</i> , 2020, 136, 40-41.	1.4	11
43	Safety and efficacy of romiplostim in patients with eltrombopagâ€resistant or â€intolerant immune thrombocytopenia. <i>British Journal of Haematology</i> , 2013, 163, 286-289.	2.5	10
44	Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. <i>Annals of Hematology</i> , 2018, 97, 73-81.	1.8	10
45	Safety and Efficacy of Granulocyte Colonyâ€Stimulating Factor Monotherapy for Peripheral Blood Stem Cell Collection in POEMS Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 361-363.	2.0	9
46	Clonal immunoglobulin Î» lightâ€chain gene rearrangements detected by next generation sequencing in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 93, 1161-1168.	4.1	9
47	Two-Year Consolidation By Nilotinib Is Associated with Successful Treatment Free Remission in Chronic Myeloid Leukemia with MR4.5: Subgroup Analysis from STAT2 Trial in Japan. <i>Blood</i> , 2016, 128, 1889-1889.	1.4	9
48	Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2019, 98, 1781-1783.	1.8	8
49	Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 517-520.	2.4	8
50	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large Bâ€cell lymphoma in a Japanese cohort. <i>British Journal of Haematology</i> , 2021, 195, 731-742.	2.5	8
51	Soluble LR11, a Novel Acute Leukemia Marker, Drastically Induces WT1 mRNA Expression Together with Synergic Activation of Gatas, and the Migration Activity. <i>Blood</i> , 2012, 120, 4795-4795.	1.4	8
52	Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2391-2394.	1.3	7
53	Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis. <i>Clinica Chimica Acta</i> , 2016, 463, 47-52.	1.1	7
54	The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group. <i>Internal Medicine</i> , 2018, 57, 17-23.	0.7	7

#	ARTICLE	IF	CITATIONS
55	EZH2 Inhibition and the Combination with Proteasome Inhibition Are Novel Potential Strategies for the Treatment of Multiple Myeloma. <i>Blood</i> , 2014, 124, 2094-2094.	1.4	7
56	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. <i>Annals of Hematology</i> , 2017, 96, 469-478.	1.8	6
57	Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. <i>International Journal of Hematology</i> , 2017, 106, 398-410.	1.6	6
58	A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. <i>International Journal of Hematology</i> , 2018, 108, 491-498.	1.6	6
59	Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 141-148.	2.1	6
60	Novel Prognostic Model Of Primary Mediastinal Large B-Cell Lymphoma (PMBL): A Multicenter Cooperative Retrospective Study In Japan. <i>Blood</i> , 2013, 122, 638-638.	1.4	6
61	Elevated TAT in COVID-19 Patients with Normal D-Dimer as a Predictor of Severe Respiratory Failure: A Retrospective Analysis of 797 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 134.	2.4	6
62	Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia. <i>International Journal of Hematology</i> , 2015, 102, 86-92.	1.6	5
63	Signalling defect in FMLP-induced neutrophil respiratory burst in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1996, 95, 482-488.	2.5	4
64	Serum soluble LR11, a novel tumor derived biomarker associated with the outcome of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2982-2985.	1.3	4
65	Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Mucosa-associated Lymphoid Tissue Lymphoma. <i>Internal Medicine</i> , 2017, 56, 3225-3229.	0.7	4
66	Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission. <i>Cancer Science</i> , 2020, 111, 2923-2934.	3.9	4
67	Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells. <i>Haematologica</i> , 2020, 105, e216-e220.	3.5	4
68	Does the Hematopoietic Cell Transplantation Specific Comorbidity Index (HCT-CI) Predict Transplant Outcomes?: A Prospective Multicenter Validation Study of the Kanto Study Group for Cell Therapy (KSGCT). <i>Blood</i> , 2012, 120, 1993-1993.	1.4	4
69	Acutely deteriorated extravascular volume overload during peripheral blood stem cell mobilization in POEMS syndrome: A case series with cytokine analysis. <i>Transfusion and Apheresis Science</i> , 2016, 54, 276-281.	1.0	3
70	Long-term complete remission by infusion of ex vivo-expanded donor-derived CD4+lymphocytes for treating an early relapse of Hodgkin lymphoma after cord blood transplantation. <i>Leukemia and Lymphoma</i> , 2016, 57, 230-232.	1.3	3
71	Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma. <i>International Journal of Hematology</i> , 2018, 108, 452-455.	1.6	3
72	Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t(5;10)(q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene. <i>Internal Medicine</i> , 2019, 58, 3449-3453.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation. <i>Blood Advances</i> , 2019, 3, 312-319.	5.2	3
74	The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. <i>Scientific Reports</i> , 2021, 11, 2074.	3.3	3
75	Efficacy of Gemtuzumab Ozogamicin (GO) Monotherapy on Relapsed/Refractory Acute Promyelocytic Leukemia (APL). <i>Blood</i> , 2011, 118, 1532-1532.	1.4	3
76	Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7054-7054.	1.6	3
77	Activation of Rac1 through FARP1 Induces Dexamethasone Resistance in Multiple Myeloma Cells. <i>Blood</i> , 2014, 124, 2248-2248.	1.4	3
78	Acute fulminant myocarditis after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning for acute myelogenous leukemia. <i>Annals of Hematology</i> , 2006, 86, 67-69.	1.8	2
79	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma. <i>International Journal of Hematology</i> , 2019, 109, 633-640.	1.6	2
80	Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation. <i>International Journal of Hematology</i> , 2021, 114, 664-673.	1.6	2
81	Serum Soluble LR11 As a Novel Biomarker for B Cell Lymphoma. <i>Blood</i> , 2011, 118, 1581-1581.	1.4	2
82	Successful treatment of two patients with hepatocellular carcinoma exhibiting severe pancytopenia caused by aplastic anemia. <i>Acta Hepatologica Japonica</i> , 2016, 57, 557-560.	0.1	1
83	Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. <i>Hematological Oncology</i> , 2018, 36, 792-800.	1.7	1
84	Identification of clonal immunoglobulin $\lambda$ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing. <i>Experimental Hematology</i> , 2021, 101-102, 34-41.e4.	0.4	1
85	High presepsin concentrations in bile and its marked elevation in biliary tract diseases: A retrospective analysis. <i>Clinica Chimica Acta</i> , 2021, 521, 278-284.	1.1	1
86	Long-Term Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial Leukocyte Counts By Using All-Trans Retinoic Acid (ATRA) Alone For Remission Induction Therapy: Japan Adult Leukemia Study Group (JALSG) APL97 Study. <i>Blood</i> , 2013, 122, 3950-3950.	1.4	1
87	Partial Splenic Embolization For The Treatment Of Steroid-Resistant Chronic Idiopathic Thrombocytopenic Purpura. <i>Blood</i> , 2013, 122, 3543-3543.	1.4	1
88	Diverse Role of DNA Hypermethylation in Reduced Expression of Tumor Suppressor NR4A3 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3640-3640.	1.4	1
89	Successful Treatment of Rapidly Progressive Life-Threatening Esophageal Submucosal Hematoma in a Patient With van der Hoeve Syndrome. <i>Journal of Clinical Medicine Research</i> , 2018, 10, 154-157.	1.2	1
90	Utx Insufficiency Cooperates with Braf V600E in the Induction of Myeloma in Mice. <i>Blood</i> , 2018, 132, 1005-1005.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Successful allogeneic bone marrow transplantation after massive gastrointestinal bleeding in a patient with myelodysplastic syndrome associated with intestinal Behçet-like disease. <i>Leukemia Research Reports</i> , 2021, 16, 100278.	0.4	1
92	Health-related QOL challenges and coping ability of patients after treatment for acute leukemia: qualitative analysis. <i>Journal of Illusion</i> , 2022, 11, 177-186.	0.1	1
93	VII. Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016, 105, 1246-1254.	0.0	0
94	Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia. <i>Case Reports in Gastroenterology</i> , 2017, 11, 29-35.	0.6	0
95	Hepatocellular carcinoma complicated by acute promyelocytic leukemia: a case report. <i>Acta Hepatologica Japonica</i> , 2017, 58, 176-182.	0.1	0
96	EFFICACY AND SIGNIFICANCE OF A CONSULTING CLINIC FOR RELATED FAMILY DONORS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AT THE DEPARTMENT OF TRANSFUSION MEDICINE AND CELL THERAPY. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2017, 63, 592-598.	0.2	0
97	T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1591-1594.	1.3	0
98	Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 221-224.	1.3	0
99	Zoledronate Can Overcome Drug Resistance in a Dexamethasone Resistant Myeloma Cell Line.. <i>Blood</i> , 2004, 104, 4894-4894.	1.4	0
100	Prognostic Impact of a Novel Biomarker, Serum Soluble LR11 on Acute Leukemia. <i>Blood</i> , 2010, 116, 2717-2717.	1.4	0
101	Sustained Superior Long-Term Outcomes of Imatinib Therapy In Japanese Patients with Newly Diagnosed Chronic Myelogenous Leukemia In Chronic Phase: Sub-Analysis According to the Mean Daily Dose of Imatinib and the Plasma Trough Levels In JALSG CML202 Study After 66 Months Follow-up.. <i>Blood</i> , 2010, 116, 3417-3417.	1.4	0
102	LR11 Is a Novel Surface Marker for Normal Leukocytes and Leukemia Cells. <i>Blood</i> , 2010, 116, 4834-4834.	1.4	0
103	Direct Activation of STAT5 by TEL-Lyn Fusion Protein Promotes Induction of Myeloproliferative Neoplasms with Myelofibrosis. <i>Blood</i> , 2010, 116, 4114-4114.	1.4	0
104	Clinical Features and Prognostic Impact of CD56 Expression in Acute Promyelocytic Leukemia: Long Term Follow up Data From the Japan Adult Leukemia Study Group(JALSG) APL97.. <i>Blood</i> , 2011, 118, 3608-3608.	1.4	0
105	Ezh2 Plays a Critical Role in the Progression of MLL-AF9-Induced Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 57-57.	1.4	0
106	Soluble LR11/SorLA, a Potential Circulating Marker Indicating the G-CSF-Induced Mobilization of Hematopoietic Stem Cells, Is a Modulator of G-CSF-Mediated Migration of HL-60 Cells,. <i>Blood</i> , 2011, 118, 3210-3210.	1.4	0
107	Role of Hematopoietic Stem Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated with All-Trans-Retinoic Acid: A Retrospective Analysis of the Japan Adult Leukemia Study Group (JALSG) APL97 Study. <i>Blood</i> , 2011, 118, 2036-2036.	1.4	0
108	Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis. <i>Journal of Hematopoietic Cell Transplantation</i> , 2012, 1, 15-23.	0.1	0



#	ARTICLE	IF	CITATIONS
109	Serum Soluble LR11 Can Predict High FLIPI-2 Score in Follicular Lymphoma.. Blood, 2012, 120, 2673-2673.	1.4	0
110	LR11 Is a Potential Serum and Histological Biomarker for Intravascular Large B-Cell Lymphoma. Blood, 2012, 120, 5104-5104.	1.4	0
111	LR11 Plays a Critical Role in Leukemogenesis of Acute Myeloid Leukemia by Regulating Adhesion and Homing Ability to Bone Marrow.. Blood, 2012, 120, 2409-2409.	1.4	0
112	Long-Term Cell Autonomous Effect of Tet2 Loss in Hematopoietic Cells in Mice.. Blood, 2012, 120, 2416-2416.	1.4	0
113	Concurrent Loss Of Ezh2 and Tet2 Cooperates In The Pathogenesis Of Myelodysplastic Disorders,. Blood, 2013, 122, 480-480.	1.4	0
114	Tetraspanin CD9 Inhibits ADAM17-Mediated LR11 Shedding In Leukemia Cells. Blood, 2013, 122, 1035-1035.	1.4	0
115	A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML). Blood, 2013, 122, 2736-2736.	1.4	0
116	The Efficacy and Long-Term Outcomes of ASCT in POEMS Syndrome: A Multicenter Retrospective Study in Japan. Blood, 2014, 124, 3970-3970.	1.4	0
117	Impact of Serum Soluble LR11 on Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Multicenter Prospective Study. Blood, 2014, 124, 1661-1661.	1.4	0
118	The Biological Function of DNA Hypermethylation in Murine MDS Model Lacking Tet2 and Ezh2. Blood, 2014, 124, 4596-4596.	1.4	0
119	Soluble LR11, GCSF $\hat{\sim}$ induced Migration Regulator from Myeloid Cells, Is Highly Increased in Chronic Myeloid Leukemia. Blood, 2014, 124, 4961-4961.	1.4	0
120	Switching to Nilotinib Are Associated with Deeper Molecular Responses in Chronic Myeloid Leukemia with Persistent Residual Disease on Long-Term Imatinib Therapy: STAT1 Trial in Japan. Blood, 2015, 126, 4032-4032.	1.4	0
121	Donor Cell-Derived Hematologic Malignancy: A Survey of Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation. Blood, 2015, 126, 859-859.	1.4	0
122	Clonal Immunoglobulin $\hat{\imath}$ Light-Chain Gene Rearrangements Detected By Next Generation Sequencing in POEMS Syndrome. Blood, 2016, 128, 4405-4405.	1.4	0
123	Oxidative Stress Levels Are Correlated with Disease Progression and Iron Overload in MDS Patients with Excess Blasts. Blood, 2016, 128, 5532-5532.	1.4	0
124	Distinctive Genetic Features of Plasma Cells in POEMS Syndrome. Blood, 2016, 128, 4404-4404.	1.4	0
125	Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study). Blood, 2016, 128, 941-941.	1.4	0
126	Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma. Blood, 2016, 128, 312-312.	1.4	0



#	ARTICLE	IF	CITATIONS
127	Role of KDM2B and Non-Canonical PRC1.1 As a Tumor Suppressor in T-ALL. Blood, 2018, 132, 2597-2597.	1.4	0
128	Detection of Clonal Plasma Cells in POEMS Syndrome Using Multiparameter Flow Cytometry. Blood, 2021, 138, 2697-2697.	1.4	0
129	Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT). Blood, 2020, 136, 28-29.	1.4	0
130	Genomic Analysis of Diffuse Large B Cell Lymphoma in a Japanese Cohort Using Targeted DNA Sequencing. Blood, 2020, 136, 14-15.	1.4	0